AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32454921
Drug: Sonophoresis procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sonophoresis procedures (0.9 W/cm2, 80% duty factor, 10 minutes duration) applied to the masticatory muscles with 25% Voltaren gel.
Trial: 35845740
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (Group B)
Trial: 33791673
Drug: TransFORM Body
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransFORM Body Treatment with TriHex Technology (TFB)
Trial: 33791673
Drug: Regenerating Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerating Skin Nectar with TriHex Technology (RSN) + TransFORM Body Treatment with TriHex Technology (TFB)
Trial: 35717995
Drug: BBV152 (COVAXIN);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBV152 (COVAXIN); two 0.5 mL intramuscular doses on days 0 and 28.
Trial: 35379563
Drug: Platinum-based doublet
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based doublet chemotherapy (standard care)
Trial: 32928754
Drug: Antibiotics prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prescribed for men aged 15 to 24 years
Trial: 32928754
Drug: Antibiotics prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prescribed for men aged 25 to 34 years
Trial: 32365732
Drug: capsules with
RxNorm normalized name: Calcium Liquid Capsules with Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules with starch-adsorbed VitD (1000 IU; 25 µg daily)
Trial: 32365732
Drug: oil-based Valens
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oil-based Valens VitD oral spray (1000 IU; 25 µg daily)
Trial: 32365732
Drug: water-based Valens
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: water-based Valens VitD oral spray (1000 IU; 25 µg daily)
Trial: 35035867
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Ultrasound-guided stellate ganglion block + Extracorporeal shock wave therapy)
Trial: 35830132
Drug: Application of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of ascorbic acid (two days after irrigation treatment)
Trial: 35830132
Drug: Non-consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-consumption of biological fertilizers
Trial: 33570647
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents and anticoagulant therapy
Trial: 36436541
Drug: Video laryngoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video laryngoscopy with supplemental oxygen (1 L/Kg per min)
Trial: 36436541
Drug: Direct laryngoscopy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct laryngoscopy with supplemental oxygen (1 L/Kg per min)
Trial: 33706870
Drug: Intensive systolic
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive systolic blood pressure treatment (<120 mm Hg)
Trial: 33000539
Drug: Fissure sealant
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fissure sealant therapy
Trial: 32960955
Drug: Vacuum bell
RxNorm normalized name: BELLADONNA
DrugBank: Belladonna (DB13913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum bell therapy and physiotherapy
Trial: 32960955
Drug: Vacuum bell
RxNorm normalized name: BELLADONNA
DrugBank: Belladonna (DB13913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum bell treatment only
Trial: 35499204
Drug: SM-88 Regimen
RxNorm normalized name: Sm-88 component racemetyrosine
DrugBank: Racemetyrosine (DB16306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM-88 Regimen (460 or 920 mg daily with methoxsalen, phenytoin, and sirolimus)
Trial: 35168531
Drug: Bisoprolol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 2.5 mg followed by combination treatment with bisoprolol 5 mg and amlodipine 5 mg
Trial: 35168531
Drug: Bisoprolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (2.5 mg - 5 mg - 10 mg)
Trial: 35168531
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with bisoprolol and amlodipine
Trial: 34280656
Drug: Higher age
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher age and longer duration of ICU treatment and mechanical ventilation
Trial: 34787258
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus verapamil (n=26)
Trial: 32388647
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic (LA) injection into the suprascapular notch
Trial: 32388647
Drug: LA and
RxNorm normalized name: rubella and mumps virus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA and corticosteroid (CS) injections into the suprascapular notch
Trial: 32388647
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (LA injection into the trapezius muscle)
Trial: 33024268
Drug: Doublets ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublets ± bev or other treatments
Trial: 34981666
Drug: 5-mg amlodipine
RxNorm normalized name: amlodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg amlodipine besylate tablets (generic formulation) in fasting trial
Trial: 34981666
Drug: 5-mg amlodipine
RxNorm normalized name: amlodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg amlodipine besylate tablets (original formulation) in postprandial trial
Trial: 32618279
Drug: ZPIV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPIV vaccine (5 μg) via standard regimen (weeks 0 and 4)
Trial: 32618279
Drug: ZPIV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPIV vaccine (5 μg) via accelerated regimen (weeks 0 and 2)
Trial: 32618279
Drug: ZPIV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPIV vaccine (5 μg) via single-dose regimen (week 0)
Trial: 35953563
Drug: treatment‐as‐usual (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment‐as‐usual (control)
Trial: 33724305
Drug: Conventional 7+3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 7+3 chemotherapy
Trial: 35035849
Drug: Combined etomidate-ketamine
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined etomidate-ketamine anesthesia (etomidate 0.3 mg/kg + ketamine 0.5 mg/kg at 5 μg/kg/min)
Trial: 36474274
Drug: Primaquine (PQ)
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine (PQ) alongside standard artemisinin‐based combination therapy (ACT)
Trial: 36474274
Drug: Standard artemisinin‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard artemisinin‐based combination therapy (ACT) without primaquine
Trial: 34274921
Drug: Trimetazidine prolong
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine prolong 80 mg once daily
Trial: 36253032
Drug: YLB113 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YLB113 (50 mg subcutaneously every 2 weeks)
Trial: 32080797
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light (BL) therapy for 45 minutes for 4 weeks
Trial: 32080797
Drug: Dim Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim Light (DL) therapy for 45 minutes for 4 weeks
Trial: 33060490
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation with low tidal volume (LTV; 6-8 mL/kg)
Trial: 33060490
Drug: Conventional tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tidal volume (CTV; 10-12 mL/kg)
Trial: 35435086
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g of boiled walnut taken daily as snacks
Trial: 33314496
Drug: Sleep-restriction therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep-restriction therapy (SRT)
Trial: 35105176
Drug: Antibiotic-Eluting Envelope
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-Eluting Envelope (AEE)
Trial: 34655181
Drug: Landiolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (10 μg/kg/min)
Trial: 33432829
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (19.2 g/day for 18 months)
Trial: 33211212
Drug: Once-weekly teriparatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly teriparatide (56.5 µg)
Trial: 33211212
Drug: Once-weekly alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly alendronate (35 mg)
Trial: 35978374
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) prior to speech-language therapy
Trial: 35978374
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) concurrent with speech-language therapy
Trial: 35978374
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) following speech-language therapy
Trial: 35978374
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation (speech-language therapy only)
Trial: 34208742
Drug: Bis-Hexanoyl (R)-1,3-Butanediol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bis-Hexanoyl (R)-1,3-Butanediol (BH-BD) 12.5 g (Days 0–7) and 25 g (Days 7–28)
Trial: 33683337
Drug: Tandem Fluzone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem Fluzone High-Dose vaccination (2 doses)
Trial: 33683337
Drug: Standard-of-care vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care vaccination (single-dose)
Trial: 32859638
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) with concurrent resistance mutation
Trial: 32859638
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) without concurrent mutations
Trial: 32859638
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) with non-pathogenic, non-resistance co-mutation
Trial: 36266613
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol 0.5% (w/w) applied twice daily for 6 weeks
Trial: 36266613
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol 0.5% (w/w)
Trial: 36266613
Drug: Placebo topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical gel
Trial: 616673046
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IR‐A and MEL
Trial: 36284454
Drug: Additional analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional analgesic consumption
Trial: 83020338
Drug: apomorphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apomorphine (5 mg)
Trial: 83020338
Drug: amantadine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amantadine (200 mg)
Trial: 32299679
Drug: Ramipril therapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril therapy (randomized arm)
Trial: 32299679
Drug: Ramipril therapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril therapy (open-label comparison)
Trial: 32299679
Drug: Ramipril therapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril therapy (combined analysis)
Trial: 35301512
Drug: Low-dose vedolizumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vedolizumab (100 or 150 mg for patients <30 kg; 200 or 300 mg for patients ≥30 kg)
Trial: 35301512
Drug: High-dose vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High-dose vedolizumab (100 or 150 mg for patients <30 kg; 200 or 300 mg for patients ≥30 kg)
Trial: 35301512
Drug: Both low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both low and high-dose vedolizumab
Trial: 34861036
Drug: Third BNT162b2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third BNT162b2 mRNA vaccine dose
Trial: 34477812
Drug: MCI Gel
RxNorm normalized name: samarium Sm153 50 MCI/ML [Quadramet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCI Gel
Trial: 35997659
Drug: Cluster 2
RxNorm normalized name: CLUSTER FIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster 2 (Almost Daily, High Pain)
Trial: 34606123
Drug: Herbal remedies
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal remedies (polyherbal decoction every 8 hr and two herbal capsules every 12 hr) plus standard care for 7 days
Trial: 32360596
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (200,000 IU initially, then 100,000 IU monthly)
Trial: 33083489
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin gel with scaling and root planing (SRP) for 7 days
Trial: 34034143
Drug: IN-MLV (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN-MLV (n = 11): 2 mL of IN MLV vaccine containing BHV1, BRSV, and BPI3V (Inforce3®)
Trial: 34034143
Drug: SC-MLV (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC-MLV (n = 10): 2 mL of MLV vaccine containing BHV1, BRSV, BPI3V, and BVDV1 & 2 (Bovi-Shield GOLD® 5)
Trial: 32331021
Drug: Cariprazine 3-12
RxNorm normalized name: cariprazine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 3-12 mg/d (flexible dosing)
Trial: 32815418
Drug: Ablation as
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablation as an adjunct to cardiac surgery
Trial: 33709997
Drug: SBIRT program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBIRT program with brief motivational intervention and referral to specialized treatment
Trial: 33725776
Drug: In-hospital physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital physiotherapy (daily post-operative physiotherapy intervention including individualized mobilization, breathing exercises, ambulation with or without a walking aid)
Trial: 34714938
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (PGE1; 25 μg)
Trial: 34714938
Drug: Slow-release dinoprostone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release dinoprostone (PGE2; 10 μg)
Trial: 34469399
Drug: No experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No experimental treatment program (control group)
Trial: 34162019
Drug: Unani formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unani formulations
Trial: 33809996
Drug: L-Glutamine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine supplementation (Gln) with physical exercises (PE + Gln)
Trial: 33809996
Drug: L-Glutamine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine supplementation (Gln) without physical exercises (NPE + Gln)
Trial: 33809996
Drug: L-Glutamine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine supplementation (Gln)
Trial: 32134713
Drug: Resveratrol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (250 mg tablet)
Trial: 32134713
Drug: Estradiol (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (0.05 mg/day transdermal patch)
Trial: 35709465
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy
Trial: 35709465
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy alone (standard therapy)
Trial: 35709465
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and cisplatin induction chemotherapy
Trial: 33046233
Drug: Left ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left ventricular reshaping with a beating heart implant
Trial: 32094049
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no implant)
Trial: 35786597
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (NIVO) first-line therapy in combination with chemotherapy
Trial: 35786597
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (NIVO) third-line or later monotherapy
Trial: 32068914
Drug: Licogliflozin 10
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 10 mg
Trial: 32068914
Drug: Licogliflozin 50
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 50 mg
Trial: 35622105
Drug: Intermittent Sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Sequential Pneumatic Compression (ISPC) device
Trial: 34318635
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppository (0.1 g/suppository)
Trial: 35279835
Drug: PCSK9-inhibiting monoclonal
RxNorm normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9-inhibiting monoclonal antibodies
Trial: 34749739
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg daily on top of standard of care for 28 days
Trial: 35440808
Drug: Office blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office blood pressure before treatment
Trial: 35440808
Drug: Office blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office blood pressure in the on-treatment follow-up period
Trial: 35075723
Drug: Topical/nasal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical/nasal administration of a probiotic assemblage (PA) of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A
Trial: 34933930
Drug: Three potentially
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three potentially neuroprotective drugs
Trial: 32106869
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) administration of diclofenac
Trial: 32106869
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of diclofenac
Trial: 35689284
Drug: Knee sleeve
RxNorm normalized name: Knee Sleeve Large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee sleeve worn for 6 weeks at least 1 hour daily (Sleeve Group, n=9)
Trial: 35129469
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) 1200 mg twice-daily for up to 5 days postoperatively
Trial: 32880953
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy Skills Training Group (DBT‐ST), n=16
Trial: 32880953
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TaU), n=15
Trial: 32212518
Drug: Luspatercept (1.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luspatercept (1.00 to 1.25 mg/kg)
Trial: 35011579
Drug: Sunitinib or
RxNorm normalized name: sunitinib Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib or Pazopanib (anti-angiogenic drugs)
Trial: 35839108
Drug: Phenylephrine combined
RxNorm normalized name: phenylephrine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine combined with Goal-Directed Fluid Therapy (GDFT)
Trial: 35839108
Drug: Goal-Directed Fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-Directed Fluid Therapy (GDFT) alone